KLP Kapitalforvaltning’s Stoke Therapeutics STOK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$229K Hold
8,800
– – ﹤0.01% 1818
2026
Q2
$288K Hold
8,800
– – ﹤0.01% 1742
2026
Q1
$287K Buy
8,800
+600
+7% +$19.7K ﹤0.01% 1681
2025
Q4
$260K Sell
8,200
-1,400
-15% -$42.1K ﹤0.01% 1741
2025
Q3
$226K Sell
9,600
-3,600
-27% -$61.7K ﹤0.01% 1781
2025
Q2
$150K Buy
13,200
+7,500
+132% +$71.2K ﹤0.01% 1890
2025
Q1
$37.9K Hold
5,700
– – ﹤0.01% 2219
2024
Q4
$62.9K Buy
+5,700
New +$70K ﹤0.01% 2211

Other funds holding STOK

KLP Kapitalforvaltning's STOK Position: Q3 2026 in Review

KLP Kapitalforvaltning held its Stoke Therapeutics (STOK) position steady in Q3 2026 at 8,800 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #1818.

KLP Kapitalforvaltning first reported a position in STOK in Q4 2024 and has held it in 8 quarters since. The position peaked at $288K in Q2 2026. 125 funds tracked by Wall St. Rank hold STOK as of Q3 2026.

  • KLP Kapitalforvaltning held 8,800 shares of Stoke Therapeutics worth $229K as of Q3 2026.
  • KLP Kapitalforvaltning left its Stoke Therapeutics share count unchanged in Q3 2026.
  • Stoke Therapeutics made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q3 2026, its #1818 holding.
  • KLP Kapitalforvaltning first reported a position in Stoke Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • KLP Kapitalforvaltning's Stoke Therapeutics position peaked at $288K in Q2 2026.
  • 125 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q3 2026, filed 10 Nov 2026.